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During the past few years there has been a rapid development in prenatal 
genetic diagnostics. New obstetric and laboratory methods have been developed and 
introduced into clinical practice. With the introduction of chorionic villus sampling 
(CVS), transvaginal sonography, early amniocentesis(AC) and first-trimester 
endoscopy, more and more anomalies can be recognised in ulero in the first trimester 
of pregnancy. These new methods can be successfully applied from the 9,h week of 
gestation. 
Currently, 4-5% of neonates are bom with congenital anomalies. One of the 
most important groups of these anomalies is the chromosomal aneuploidies, among 
which the numeric chromosomal aneuploidies have the greatest clinical role. The 
prevalences of Down, Edwards and Patau syndromes at birth are 1/700, 1/3000 and 
1/5000, respectively, and they rise with maternal age. Prevention plays a great role, as 
these illnesses cannot be cured or treated efficaciously. The other important group is 
the structural anomalies, prevention of which should also be emphasised. 
The primary prevention is the avoidance of the development of the disease, but 
this is possible in only a small percentage of congenital anomalies. During the 
secondary prevention, suspicious cases should be recognised. This secondary 
prevention should be simple, effective, economically viable, painless, safe and 
humane. 
There is a high-risk group of pregnants: 
A. those over 35 years old, as the risk of trisomies gradually rises with the age 
of the mothers, 
B. those with previous chromosomal aneuploidy in their family (parental or 
neonatal), 
C. those whose ultrasound screening shows any type of abnormality. 
These pregnants should be screened carefully and invasive testing such as CVS, AC, 
chordocentesis (CC), or analysis of serum or urine biochemical 
markers should be offered to them if necessary. 
A possible diagnostic method for the detection of 
trisomy 21, other chromosomal aneuploidies, foetal cardiac 
defects and certain genetic syndromes in the first trimester is 
the screening of increased nuchal translucency (NT) thickness. 
NT is defined as the normal subcutaneous space, observed on 
first-trimester ultrasound examination, between the skin and 
the soft tissue overlying the cervical spine in the foetus. This 
space can be increased in size in the presence of a cystic 
hygroma or nuchal oedema, both of which can be detected in 
the first trimester. Cystic hygroma are bilateral, septated cystic structures that present a 
congenital malformation of the foetal lymphatic system, resulting in overdistension of 
the jugular lymphatic sacs. NT, also known as nuchal oedema, is caused by the 
subcutaneous accumulation of fluid resulting in a simple, non-septated lesion. 
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Although cystic hygroma are often associated with Turner syndrome, a simple NT is 
more often associated with other aneuploidies, particularly Down syndrome. In 1990, 
Szabo and Gellen first reported the correlation between a nuchal fluid accumulation >3 
mm in the first-trimester foetus and trisomy 21. In addition to this association with 
aneuploidy, multiple studies have now identified an increased NT thickness as a non-
specific marker of a range of foetal structural abnormalities and various genetic 
syndromes. 
Congenital heart defects (CHDs) are the most common congenital 
abnormalities, with a prevalence of 3-8 per 1000 pregnancies, i.e. 30% of the total 
congenital malformations, but most of them are not identified in the course of routine 
antenatal scanning. At present, screening for cardiac defects is routinely undertaken as 
part of the second-trimester scan, at 18 to 22 weeks of gestation, by examining a four-
chamber view. Evaluation with foetal echocardiography at 20 weeks of gestation can 
identify approximately 70% of major cardiac abnormalities. However, identification of 
those pregnancies that require this specialised evaluation remains a challenge. 
Currently, general population screening for foetal cardiac anomalies is based on 
maternal and family history, together with examination of the four-chamber view of 
the heart during routine ultrasound at 18 to 20 weeks of gestation. A recent screening 
study examining the sensitivity of the four-chamber view at 16 to 20 weeks' revealed 
an identification rate of only 26% of major cardiac defects. Another study reported a 
sensitivity of 61% on examination of the four-chamber view and the outflow nacts. as 
well. The sensitivity of second-trimester cardiac screening can be increased to 
approximately 80% by inclusion of the outflow tracts during sonographic evaluation. 
On the other hand, there is another method, which combines prenatal screening 
for cardiac defects and the assessment of first-trimester foetal NT thickness. An 
association between cardiac defects and increased NT thickness has been recognised in 
the first trimester. Four studies have reported a 81% detection score of foetal cardiac 
defects by using a first-trimester thickened NT. To further assess the relationship 
between cardiac defects and foetuses with abnormal karyotype and increased NT 
thickness, Hyett et al. reported on a pathological examination of the foetal heart after 
first-trimester termination of pregnancy (TOP) in 36 foetuses with increased NT 
thickness and trisomy 21. This evaluation showed atrioventricular or ventricular septal 
defects (ASD, VSD) in 56% of these foetuses, with the incidence of cardiac septal 
defects increasing with NT. Studies have also shown that there is an association 
between cardiac defects and increased NT in chromosomally normal foetuses. Hyett et 
al reported pathological findings observed from the examination of 21 chromosomally 
normal foetuses with increased NT after TOP. Abnormalities of the heart and great 
vessels were found in 19 (90%) of the 21 cases. Other studies have reported major 
cardiac defects in more than 75% of foetuses with trisomy 21 and trisomy 18, in which 
NT was greater than 4 mm. Hyett et al. also found that the prevalence of major 
cardiac defects among 1389 chromosomally normal foetuses from a high-risk 
population with a foetal NT greater than the 95ch percentile at 10 to 14 weeks of 
gestation increased with the NT. In that study, the prevalence of major abnormalities 
of the heart and great vessels was 17 per 1000. Hyett et al. completed a retrospective 
review evaluating 29,154 singleton pregnancies from an undefined patient population 
with presumed normal karyotype. Six groups of major cardiac defects were identified 
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in this series. Although increased NT was observed with all types of major 
abnormalities of the heart and great vessels, there was a stronger association with 
hypoplastic left heart syndrome (HLHS) and coarctation of the aorta. HLHS is the term 
used to describe a group of congenital heart lesions characterised by severe 
underdevelopment of the left heart structures. This association with left-sided defects 
is supported by a series published by Moselhi et al., which identified increased NT as a 
possible marker for coarctation of the aorta. 
Several case reports and small series have also suggested that, in 
chromosomally normal foetuses, there may be an association between first-trimester 
increased NT thickness and a wide range of foetal abnormalities and genetic 
syndromes. The overall incidence of associated structural malformations in these 
studies ranges from 3% to 7S%, with emphasis on cardiac, renal and skeletal 
anomalies, omphalocele and diaphragmatic hernia. 
Therefore, it seems that increased NT thickness in the first trimester is 
associated with an increased risk of major foetal cardiac and structural abnormalities. 
This increased risk is present in both euploid and aneuploid pregnancies and seems to 
be proportionate to the degree of NT enlargement. 
Differences in sex ratios have been noted in cases involving the main trisomies 
(trisomy 13, 18 and 21). Sex ratio is defined as the number of males divided by the 
number of females (sometimes multiplied by 100). The primary sex ratio is that 
observed at conception, and the secondary one is that at birth. Extrapolations suggest 
that the primary sex ratio for all conceptions of whites may be approximately 1.15; 
among live births, it is calculated to be 1.06-1.07, the same as in Hungary. The major 
factor affecting the secondary sex ratio appears to be race, with a low of 1.02 in 
American Indians, and a high of 1.15 reported in Korea. 
It is frequently suggested that males are more at risk of foetal wastage than 
females, and that the sex ratio at birth therefore reflects the health of the intrauterine 
environment, a high sex ratio indicating a good environment, and a low sex ratio an 
adverse one. 
2. AIMS 
The main aim of my studies was to gain a better insight into the possibilities 
provided by first-trimester ultrasound screening for foetal aneuploidies and other 
structural abnormalities. 
1. Examination of the effectiveness of first-trimester ultrasound in the 
screening of foetal aneuploidies. 
2. Standardisation of the conditions of prenatal screening, setting up a cut-off 
level of NT thickness. 
3. The literature contains controversial data on the sex ratio of foetuses and 
neonates with trisomy 21, 18 and 13. Accordingly, we reinvestigated this 
issue by analysing these trisomies. 
4. Study of the association between first-trimester increased NT thickness and 
foetal cardiac defects, especially HLHS. 
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5. Establishment of a first-trimester ultrasound scan programme to screen 
foetal aneuploidies and cardiac defects. 
6. Evaluation of the number of pregnants who take part in genetic counselling, 
and improvement of its efficacy. 
3. MATERIALS AND METHODS 
All of my examinations were performed at the Department of Obstetrics and 
Gynaecology, at four regional hospitals and at the Department of Medical Genetics, 
Faculty of General Medicine, Albert Szent-Györgyi Medical and Pharmaceutical 
Centre, University of Szeged, Szeged, Hungary. 
3.1. NT thickness measurement 
The ultrasound examinations were performed by using a 6.5-7.5 MHz vaginal 
probe (Combison 530, 3D, Kretz Technik). The NT thickness was measured at 10-13 
weeks of gestation between the outer skin surface and the soft tissue overlying the 
foetal spine in the sagittal plane of the foetus in a "quiet or neutral" position. The 
maximal zoom of the ultrasound screen was used. The foetal NT thickness was 
evaluated only after embryo movements, in order to distinguish between the foetal skin 
contour and die amnion. The number of foetuses, the crown-rump length (CRL), the 
foetal movement and heart activity, the extremities and foetal structural anomalies 
were also evaluated. NT thicknesses of >2.5 mm were defined as positive cases and 
were referred from the regional hospitals to our tertiary genetic counselling clinic for 
consideration of an invasive test. Informed consent was obtained before ultrasound 
examinations and invasive testing, and all the women participated in the study 
voluntarily. 
All the sonographers involved had received a licence for first-trimester scanning 
after theoretical and practical training at our centre. 
3.2. Invasive testing 
Invasive tests were offered according to the classical genetic indications, i.e. a 
maternal age ¿35 years, a previous child with chromosomal abnormalities, parental 
chromosomal abnormalities, and a NT ¿2.5 mm. Women could choose between an 
earlier rapid test (CVS), or later AC or CC. Invasive tests were offered to patients over 
35 years of age, irrespective of the NT, in accordance with the current legal regulations 
in Hungary. The invasive procedures were performed transabdominally with 
ultrasonically guided needles, using a freehand technique. The outer diameters of the 
CVS, AC and CC needles were 1.1 mm, 0.8 mm and 0.8 mm, respectively. 
3.3. Follow-up 
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For those who declined invasive tests, a thorough ultrasound follow-up was 
advised in order to seek early second-trimester markers of foetal aneuploidies such as 
an increased NT thickness, cardiac defects, echogenic bowels, pyelectasis, and other 
structural defects, combined with the alpha-foetoprotein (AFP) level at 16 weeks of 
gestation. All other women underwent an anomaly scan at weeks 18 to 20. 
Information on the pregnancy follow-up and outcome was obtained through 
written questionnaires or by telephone from the patients, from the regional hospitals 
and/or from the nursing midwife network. 
3.4. Foetal aneuploidies 
In a prospective screening study between 1995 and 1998 at the Szeged 
University Prenatal Clinic and at four regional hospitals, the NT thickness was 
measured at 10 to 12 weeks of gestation by transvaginal ultrasound examination in 
7044 women with singleton or multiple pregnancies. Informed consent was obtained 
before ultrasound examinations and invasive testing, and all the women participated in 
the study voluntarily. 
The study did not cover the whole population in the region, in spite of the 
increasing quantity of available information on the importance of first-trimester 
ultrasound screening. 
From October 1997, we used in parallel the USS program kindly provided by 
Professor Nicolaides from the Foetal Medicine Foundation, London, but NT thickness 
of 2.5 mm remained as an interventional cut-off. 
3.5. Cardiac defects 
The pre- and postnatal findings, the course and outcome of the pregnancies and 
the relationship between the first-trimester foetal NT thickness and foetal CHDs in 
euploid foetuses were retrospectively analysed in 4309 pregnancies that ended with 
birth or therapeutic abortion at the Department of Obstetrics and Gynaecology, 
University of Szeged, between 1 January 1998 and 30 June 2000. 
At our Department, routine foetal echocardiography has been performed in 
high-risk cases since 1 October 1999. The pregnants in the high-risk group have 
• A family history of CHD, 
• maternal diabetes mellitus, 
• maternal systemic lupus erythematosus (SLE), 
• teratogen exposure, 
• any type of foetal malformation, 
• intrauterine growth retardation (IUGR), 
• chromosomal anomalies. 
However, this examination was also made in suspicious cases during this period. 
Newborns were examined on the first and fourth postnatal days by a 
neonatologist. In the event of any clinical sign of CHD (i.e. cyanosis, a murmur, an 
increased oxygen requirement or fatigue), a paediatric cardiologist was involved in 
exploring the diagnosis. 
3.6. Sex ratio 
Three sources of data were used for analysis of the sex ratios of the prenatal and 
live birth cases: 
1. the prenatal register of aneuploidies of Szeged between 1990 and 1999, 
2. the Down register of Szeged between 1970 and 1999. 
3. the Down register of Hungary between 1970 and 1999. 
These registers contain data on the mother (name, age and address) and on the 
foetus or the child (gestational age at karyotyping, karyotype, date of TOP and 
outcome of pregnancy). During the statistical analysis, chi-square probe was used. 
4. RESULTS 
4.1. Foetal aneuploidies 
Between January 1995 and December 1998, 7044 women were enrolled in the 
first-trimester ultrasound screening study. Of these, 203 were excluded from further 
analysis since it was impossible to obtain any written or oral information concerning 
the pregnancy outcome. 
As regards the remaining 6841 pregnancies, 4821 were examined in the regional 
centres and 2020 (29.5%) were referred to or primarily examined at the Department of 
Obstetrics and Gynaecology. There were 6750 (98.67%) singleton and 91 (1.33%) 
multiple pregnancies (85 sets of twins, 3 sets of triplets, 2 sets of quadruplets and I set 
of quintuplets). The 2 sets of quadruplets and the quintuplet pregnancy were each 
reduced to 2 foetuses at the request of the parents. Ail these multiplets were euploid. 
Spontaneous abortion occurred between the NT screening and the planned invasive 
tests in 8 patients, and up to week 20 in another 15 pregnancies. 
The median maternal age was 31 years (Tange 16-46). The NT was >3 mm in 
191 (2.8%) and ¿2.5 mm in 308 (4.5%) cases, to whom invasive tests were offered: 
however, 54 declined. 
An abnormal karyotype was found in 33 (0.48%) cases, i.e. 5.4% of the total 
number of those who participated in invasive examinations. A NT >2.5 mm was 
measured in 32 (96.97%) of the foetuses with an abnormal karyotype. For a cut-off of 
3 mm, this changed to 84.8%. In the group of invasive tests based on maternal age and 
previous chromosomal abnormalities (353 cases), only 1 chromosomal aneuploidy was 
found. 
The mean NT values were 3.76 mm for trisomy 21, 5.75 mm for trisomy 18 and 
4.23 mm for trisomy 13. The maternal age was >35 years in 18 (54.54%) of the 33 
aneuploid pregnancies. A foetal NT thickness <3 mm (2.8 mm) was measured in only 
1 of the 15 mothers <35 years of age (33 years old), while 4 of the foetuses of the 18 
women aged >35 years had a NT thickness <3 mm (1.2, 2.5, 2.8 and 2.9 nun). 
Tables I and II present the sensitivity, the specificity, the positive and negative 
predictive values and the false-positive rate for cut-off values of 2.5 mm and 3 mm in 
all aneuploid cases and in cases with trisomy 21. 
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Table I. Efficiency of NT screening with a cut-off level of >2.5 mm for all 
aneuploidies and trisomy 21 
All aneuploidies (%) Trisomy 21 (%) 
Sensitivity 96.97 100 
Specificity 95.94 95.74 
Positive predictive value 10.39 5.52 
Negative predictive 99.98 100 
value 
False-positive rate 4.05 4.26 
Table II. Efficiency of NT screening with a cut-off level of >3 mm for all 
aneuploidies and trisomy 21 
All aneuploidies (%) Trisomy 21 (%) 
Sensitivity 84.85 76.47 
Specificity 97.61 97.39 
Positive predictive value 14.66 6.81 
Negative predictive 99.92 99.94 
value 
False-positive rate 2.39 2.61 
4.2. Cardiac defects 
Between January 1998 and June 2000, 4251 births and 58 therapeutic abortions 
(altogether 4309 pregnancies) were recorded at our Department of Obstetrics and 
Gynaecology. At birth, 151 congenital malformations were diagnosed; 34 of them 
were known prenatally. In the 58 pregnancies that ended with therapeutic abortion, 
there were 22 foetal chromosomal abnormalities, 19 neural tube defects and 17 severe 
multiple foetal malformations. Altogether, 209 (4.9%) congenital malformations were 
detected, 39 (18.7%) of which were CHDs. Eight of the 39 CHDs were diagnosed by 
foetal echocardiography, while the others were suspected on neonatal examination and 
were confirmed by ultrasonography. The prevalence of major CHDs was 9 per 1000 
pregnancies (39/4309). 
First-trimester foetal NT was measured in 35 of the 39 foetuses with CHDs: it 
was >3 mm in 18 (51.4%) and <3 mm in 17 (48.6%). The NT was not measured in 4 
foetuses with CHDs. There were 3 foetuses with prenatally detected severe CHDs 
combined with other structural abnormalities. The NT thickness was >3 mm in all 3 
cases. With regard to the virtual certainty of extremely unfavourable outcomes of these 
3 pregnancies, therapeutic abortion was offered (after careful and extensive non-
directive counselling) by members of the University Foetal Board (obstenician-
sonographer, paediatric cardiologist, neonatologist, heart surgeon and geneticist). In all 
3 cases, the couples opted for therapeutic abortion, which was performed in weeks 17. 
22 and 23, respectively. Autopsy confirmed the prenatal findings. 
The CHDs were classified into 5 main groups: HLHS; VSD and ASD; tetralogy 
of Fallot; transposition of the great vessels: and others. An increased first-trimester NT 
was found predominantly in foetuses with defects in the left-heait tract (75%) or with 
ASD or VSD (58.8%). AH foetuses with n ansposition of the great vessels had a NT <3 
mm. The numbers indicate only the tendency, and are insufficient for a statistical 
evaluation. 
A sensitivity of 51.4%, a specificity of 97.6%, a positive predictive value of 
17.8%, a negative predictive value of 99.5% and a false-positive rate of 4.1% were 
found at a cut-off of 3 mm. The measurement of increased NT for the detection of 
foetal cardiac abnormalities had sensitivities of 51.4% and 71.9 % at a cut-off of 3 and 
2 mm, respectively. 
4.3. Sex ratio 
In the cases of prenatally diagnosed chromosomal abnormalities between 1990 
and 1999, the sex ratios were 1.48 (43/29) for trisomy 21, 0.375 (6/16) for trisomy 18 
and 2.0 (6/3) for trisomy 13. In cases of postnatal karyotyping, the sex ratios were 
1.44 (118/82), 0.5 (2/4) and 3.0 (3/1), respectively. 
The Down register of Szeged contained Down's cases between 1970 and 1999; 
in the early years, it contained only the data on the postnatally diagnosed cases, but 
later on both the pre- and postnatally diagnosed ones. The total number of cases was 
441 and their sex ratio was 1.41. Taking into consideration only the prenatally 
diagnosed ones (72 cases), the sex ratio was 1.48; for the postnatal cases (369 cases) it 
was 1.4. 
The Down register of Hungaiy contained 5531 cases. The number of prenatally 
diagnosed cases in this register was 505 (the sex was unknown in 20 cases), with a sex 
ratio of 1.16 (260/225), while in the 5026 postnatally diagnosed cases (the sex was 
unknown in 21 cases) it was 1.18 (2709/2296). These data suggested that there is no 
significant difference in intrauterine lethality between males and females. 
When the data in the registers of Szeged and Hungary were compared, no 
significant difference was found either prenatally (P=0.886, OR=0.922, 95% 
CI=0.526-1.613) or postnatally (P=0.669, OR=0.869, 95% CI=0.496-1.522). 
5. DISCUSSION 
Efforts are currently being made worldwide to achieve the recognition of foetal 
chromosomal aneuploidies at the earliest possible gestational age. Increased NT have a 
prognostic significance, especially when found in association with other foetal 
anomalies. Although the exact pathophysiology of increased NT is uncertain, the cause 
of this transient event may be connected with alterations in foetal haemodynamics 
and/or alterations in lymphatic drainage. 
The heterogeneity in conditions associated with increased NT thickness 
suggested that there may not be a single underlying mechanism for the subcutaneous 
oedema in the foetal neck. Possible mechanisms include: 
• Cardiac failure in association with abnormalities of the heart and great 
arteries; 
• Venous congestion in the head and neck in association with the constriction 
of the foetal body in amnion rupture sequence, or superior mediastinal 
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compression found in diaphragmatic hernia, or the narrow chest in skeletal 
dysplasia: 
• Failure of lymphatic drainage due to impaired foetal movements in various 
neuromuscular disorders; 
• Abnormal or delayed development of the lymphatic system; 
• Altered composition of the subcutaneous connective tissue. 
5.1. Foetal aneuploidies 
Though a number of second-trimester ultrasonic markers of foetal aneuploidies 
have been described, such as a thickened nuchal pad, heart defects, a shorter humerus 
and femur, echogenic bowels, pyelectasis, etc., none of them is specific and of value 
for efficient screening. Moreover, the search for these sonographic markers is time-
consuming, and demands exceptional training, qualifications, experience and 
competence in ultrasound examinations. 
The report by Szabo and Gellen that the accumulation of nuchal fluid >3 mm 
thick as measured by high-resolution ultrasonography in the first-trimester embryo is 
associated with trisomy 21 is gaining increasing acceptance worldwide. First-trimester 
NT screening for chromosomal aneuploidies is ever more widely utilised, but the 
efficiency is extremely variable: between 30 and 90%. In Szeged, from the start we 
have placed special emphasis on the analysis of factors influencing the efficiency, and 
in the learning years we have maintained a high rate of efficiency (88%). 
The Department of Medical Genetics is the only centre in South Hungaiy where 
all prenatal counselling and cytogenetic studies are performed and to which all 
neonates with any indications of abnormality are referred. The ultrasound clinic is a 
third-level screening centre. 
Cut-off levels: The cut-off levels of first-trimester NT thickness used by 
different authors range from 2 to 5 mm. In practice, we use a 2.5 mm cut-off. Since the 
frequency of a NT thickness >3 mm in the general population is 2-3%. invasive testing 
of these selected pregnancies means an appreciable load for genetic centres. If we use 
a lower cut-off, we can detect more foetal aneuploidies. but the work-load increases 
significantly. A practically acceptable cut-off value is therefore necessary to 
distinguish affected cases from normal ones. It is known that the NT thickness 
normally increases with the CRL, and the use of a single cut-off may bias the 
sensitivity. If the NT screening concentrates on weeks 11 to 12, a cut-off of 2.5 mm, 
which yields more than 90% sensitivity, is acceptable in practice. 
With a cut-off of 3 mm or higher, the reported sensitivity for all aneuploidies 
ranges between 46% and 69%, and that for trisomy 21 between 54% and 77%. The 
sensitivity we obtained by using a 2.5 mm cut-off (96.97% for all aneuploidies and 
100% for trisomy 21) is highly comparable with the literature data. 
Recent studies have used cut-off levels calculated via percentile curves or the 
risk calculation program of the Foetal Medicine Foundation, UK. This program 
calculates the risk of aneuploidies from a combination of the maternal age and the 
gestational age-related prevalence, multiplied by a likelihood ratio depending on the 
deviation from the normal in NT thickness for the CRL. Use of a risk calculation 
involving a combination of the maternal age, gestational age, NT thickness and former 
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aneuploidy allowed the setting-up of a risk cut-off level >1:300. The method of risk 
calculation reported by Snijders et al. is a more comprehensive approach, which 
collects the known factors responsible for the actual risk of aneuploidy. Their risk 
calculation program led to a detection rate of 82% for Down syndrome and of 78% for 
other chromosomal aneuploidies. 
In our opinion, it is useful to set up a standard of first-trimester ultrasound 
screening with a well-defined cut-off level, as there are centres in the developing areas 
which do not have the facilities to establish a computer calculation network. In 
addition, our study was conducted before the Foetal Medicine Foundation risk 
calculation was available. A well-defined cut-off level is of practical value for 
sonographers trained in NT measurement who screen in underdeveloped regions far 
from the centres and who need a practical solution. Our results suggest that 2.5 mm at 
10 to 12 weeks of gestation is a reasonable cut-off level for those who do not have the 
programme, as this yields an acceptable rate of first-trimester detection of foetal 
aneuploidies. 
Efficiency of NT screening with a cut-off of 2.5 mm: Both in our regional 
i perinatal centre and in Hungary overall, the proportion of pregnants aged over 35 years 
has been around 7% during the last decade. The regulations require that they should be 
offered invasive tests, which result in only a 12-15% detection rate of trisomy 21 at 
50% uptake. With a NT'thickness of >2.5 mm, in the present study 4.5% of all 
' pregnancies screened positive and they included 100% of the trisomy 21 cases and 
96% of all aneuploidies. The sensitivity obtained in the literature studies lay in the 
range 50-92% for all aneuploidies and in the range 43-88% for trisomy. 
In experienced hands, ultrasonographic evaluation of the foetus at 10 to 12 
gestational weeks is one of the most efficient methods of screening chromosomal 
abnormalities. In the group of 353 women with a NT thickness of <2.5 mm who 
underwent invasive tests, only one aneuploidy (trisomy 18) was found; this suggests 
that the measurement of NT thickness alone is a good selection criterion for invasive 
tests. A NT cut-off of ¿2.5 mm is a sensitive and effective criterion of selection of 
women for invasive tests. 
The recognition of foetal aneuploidies at this gestational age and the early 
termination of the affected pregnancy may be less traumatic for couples who choose 
this option and they may have a healthy offspring sooner. A potential disadvantage of 
this early diagnosis is the identification of chromosomally abnormal pregnancies that 
are destined to miscarry. About 40% of trisomy 21 foetuses die between 12 weeks of 
' gestation and term. Other benefits of the first-trimester scan include the confirmation 
that the foetus is alive, accurate dating of the pregnancy, the early diagnosis of 
multiple pregnancies and the detection of major structural abnormalities and missed 
abortion. General evaluation of the foetal structure simultaneously with NT 
' measurement can reveal other structural abnormalities and allow efficient genetic 
counselling to be extended to more and more women, irrespective of their age. 
5.2. Cardiac defects 
Screening for CHDs at the earliest possible stage of gestation is an important 
task, but a great challenge in prenatal diagnostics. Foetal echocardiography in the 
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second or (more recently) the first trimester of pregnancy has been found to be a 
promising screening method for CHDs. Evaluation of the four-chamber view of the 
heart and the outflow tracts in the second trimester of pregnancy yielded a sensitivity 
as high as 61%. 
An earlier and a higher rate of detection of foetal CHDs was found when 
ultrasound measurement of increased foetal NT thickness (>3 mm) at weeks 10 to 13 
of gestation was demonstrated to be associated with foetal cardiac malformations. The 
findings in most of the publications are in accord from this respect, but Schwarzler ci 
al. were not able to confirm such an association in an unselected population. 
Cut-off levels: The prevalence of major CHDs increases in parallel with the NT 
thickness and Zosmer et al. suggest the 95,h centile of NT thickness as a cut-off at 
which the follow-up of such pregnancies by sonographers and specialists in foetal 
echocardiography is recommended. Our data indicate that screening on the basis of an 
increased NT thickness, with a cut-off of 3 mm, identifies 51.4% of the major 
abnormalities of the heart and great arteries at weeks 10 to 13 of gestation. The results 
compare favourably with the data reported by Hyett et al.. An even higher detection 
rate of 71.9% (23/32) can be obtained at a cut-off value of ¿2 mm. Since the rate of a 
NT thickness >3 mm in the general population is between 2 and 3%, ultrasound 
follow-up of these selected pregnancies means an extra load for specialists in foetal 
echocardiography. If we use a lower cut-off, we can detect more foetal CHDs, but the 
work-load will increase significantly. A practically acceptable cut-off value is 
therefore necessary to distinguish cases marked for follow-up. It is known that the NT 
thickness normally increases with CRL and the 95th centile is 2.2 mm for a CRL of 38 
mm, and 2.8 mm for a CRL of 84 mm and the use of a single cut-off may bias the 
sensitivity. We consider that a 3 mm cut-off yielding a 51.4% sensitivity is practically 
acceptable, especially if the NT screening concentrates on the period between weeks 
U and 12. 
Types of foetal CHDs screenable via an increased NT: We found an association 
between the type of foetal CHDs and an increased NT. A HLHS and septal defects 
displayed stronger associations with an increased NT. This observation is comparable 
with previous reports of the highest detection rate in cases involving a HLHS. 
Follow-up and clinical management of pregnancies with an increased NT and a 
normal karyotype: An increased foetal NT thickness at weeks 10 to 13 of gestation is 
associated with foetal aneuploidies, cardiac and other structural abnormalities and 
certain genetic syndromes. Since an increased NT accompanies such a wide range of 
foetal abnormalities, careful clinical management should be observed. Our policy is 
first to determine the foetal karyotype; in chromosomally normal foetuses, a thorough 
ultrasound follow-up is recommended, including targeted foetal echocardiography and 
scanning for structural abnormalities and genetic syndromes. 
Spontaneous resolution of nuchal oedema occurs in 90% of pregnancies with an 
increased NT and a normal karyotype. These pregnancies will result in normal 
neonates. Only the remaining 10% of foetuses with an increased NT need further 
evaluation (with targeted foetal echocardiography), which does not mean too great an 
overload for the medical personnel. 
Though the issue of whether the antenatal diagnosis of CHDs affects the 
postnatal outcome is still controversial, most authors favour an early prenatal diagnosis 
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to avoid long-term cardiac and neurological consequences. Newborns with cardiac 
abnormalities should be born in hospitals where all appropriate cardiological facilities 
are available. Adequate care can then be provided in due time for the neonatal cardiac 
patient. 
In conclusion, an increased foetal NT at weeks 10 to 13 is an important 
predictor and efficient method of screening, not only for foetal aneuploidies, but also 
for foetal cardiac abnormalities, and particularly left-sided defects. 
5.3. Sex ratio 
The excess of males in Down syndrome has long been recognised. An earlier study 
reported a value of 1.23 for the sex ratio of Down syndrome in England and Wales. In 
Edwards syndrome, a low sex rate was noted as early as 1962 and has since been 
confirmed in other studies. In the study by Goldstein and Nielsen in 1988, the sex 
ratio for trisomy 18 was 0.64. Combined data from these two studies suggest that the 
sex ratio in prenatally diagnosed cases (0.82) may be greater than in postnatally 
diagnosed ones (0.52), with the implication that the in utero survival in male trisomy 
18 is poorer than in females. 
Huether et al. suggested that the foetal sex ratio estimate for trisomy 21 was 
1.16, while in the prenatal controls it was 1.07. The live birth sex ratio estimate for 
Down syndrome was 1.15, while in the postnatal controls it was 1.05. Both the pre-
and postnatal data were significantly different from the pre- and postnatal controls. 
We can confirm earlier reports of the male excess in Down syndrome, using 
different Down registers. Both our pre- (1.48) and our postnatal (1.44) ratios were 
higher. On the basis of the Hungarian Down register, the prenatal sex ratio was 1.16 
and the postnatal one was 1.18. The cause of the male excess in trisomies 21 and 13 
has not been established, but there are some possible explanations. 
Sex ratios in trisomy 21: 
Hassold et al. proposed that the increased sex ratio for Down syndrome is 
associated with a paternal non-disjunction, where the extra 21st chromosome 
preferentially segregates with the Y chromosome. 
Petersen et al. provided data based upon DNA polymorphisms and gave 
strongly supportive evidence. They found a sex ratio of 3.5 in those cases where the 
extra 21s1 chromosome was paternally derived through a meiotic non-disjunction. 
With regard to the recent molecular evidence which indicates that only - 5 % of 
Down syndrome non-disjunctions are paternally derived, and assuming a sex ratio of 
1.06 for all maternally derived cases, a sex ratio of 3.5 is exactly that needed in 
paternally derived cases to reach an overall sex ratio of 1.18. Huether et al. confirm 
that the lack of any maternal age effect for either foetuses or live births is also 
evidence in support of the higher sex ratio being paternally derived in Down 
syndrome. 
James considers that the cause of this male excess in Down syndrome is not the 
sex-selective spontaneous abortion, but rather the timing of insemination in relation to 
ovulation is not optimal. It is widely believed (at least among non-geneticists) that the 
timing of fruitful coitus within the human menstrual cycle is associated with the 
offspring sex ratio, male zygotes being preferentially formed when the fruitful 
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insemination is either early or late. In a meta-analysis on this point. Gray estimated 
that fruitful inseminations around ovulation have a relative risk of only 90% of 
yielding males as contrasted with early or late inseminations. 
Sex ratios in trisomy IS: 
In the study by Goldstein and Nielsen, the sex ratio for trisomy 18 was 0.64. 
which means a female excess. Combined data from the studies by Taylor and 
Goldstein and Nielsen suggest that the sex ratio in prenatally diagnosed cases (0.82) 
may be greater than that in postnatally diagnosed ones (0.52), with the implication 
that the in tilero survival in male trisomy 18 is poorer than in females; however, the 
difference was only marginally significant. 
Huether et al. demonstrated that in trisomy 18 the foetal sex ratio estimate was 
0.9, while in the prenatal controls it was 1.07. The live birth sex ratio estimate was 
0.63, while in the postnatal controls it was 1.05. Both the pre- and the postnatal data 
were significantly different from the pre- and postnatal controls. Our data were 
considerably lower than in the former studies: the prenatal sex ratio for Edwards 
syndrome was 0.375, and the postnatal one was 0.5. 
Sex ratios in trisomy 13: 
In the study by Huether et al., the foetal sex ratio estimate was 0.88, while in the 
prenatal controls it was 1.07. The corresponding data in the live birth cases were 0.9 
and 1.05, respectively. Our estimated sex ratios for Patau syndrome were the opposite 
of the literature data, though the number of cases was quite low. The prenatal sex ratio 
was 2, and the postnatal one was 3. 
Study of the differences between the sex ratios of the autosomal trisomies, and 
molecular genetic study of the non-disjunction of the chromosomes of trisomies 13. 
18 and 21, can furnish further data about the genesis of these trisomies. 
6. CONCLUSIONS 
Recent advances in medical technology have allowed more emphasis to be 
placed on first-trimester screening and the diagnosis of foetal congenital 
malformations and chromosomal abnormalities. As these screening programs are 
implemented, sonographic evaluation of foetal anatomy will potentially also occur at 
an earlier gestational age. Improved ultrasound resolution has allowed us to evaluate 
foetal anatomy in the late first trimester, including the detection of ultrasound markers 
for foetal aneuploidy and structural malformations. The NT thickness has been 
identified as a sonographic marker for foetal aneuploidy and strucMra! malformations, 
especially cardiac abnormalities. NT screening has a function for the identification of 
patients at high risk of cardiac anomalies who may benefit from foetal 
echocardiography or follow-up evaluation. In addition, an increased NT can be useful 
for counselling patients concerning the prognosis for pregnancy. 
We hope that NT thickness measurement will be a useful screening tool to 
identify patients from the low-risk population for further examination, such as targeted 
foetal ultrasound and possibly foetal echocardiography. In the interim, it is reasonable 
to recommend that if the NT thickness is >2.5 mm at 10 to 13 gestational weeks. 
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referral should be made to a tertiary care centre for targeted sonographic examination 
to assess for foetal anomalies. 
First-trimester screening is currently offered in more than 200 centres in 41 
countries throughout the world. A total of more than 100,000 women have been 
examined and 80% of foetuses with chromosomal abnormalities have been identified. 
This compares favourably with the detection rates achieved with screening based on 
maternal age (a detection rate of about 30%) or maternal age and serum biochemistry 
(a detection rate of about 60%). 
Besides the detection of chromosome defects, the scan provides important 
information in twin pregnancies and early scans help to identify pregnancies with an 
increased risk of cardiac defects or genetic syndromes. 
Conclusions of the thesis: 
1. NT thickness measured by ultrasound in the first trimester is a reliable 
marker of foetal chromosomal abnormalities. 
2. First-trimester ultrasound screening is one of the most effective methods of 
screening foetal anomalies, especially major cardiac defects, which are 
detectable by ultrasound examination. 
3. The method is safe and has no adverse effects on the foetus or the 
pregnancy. 
4. A NT thickness of 2.5 mm or higher is a warning sign of a possible 
chromosomal abnormality or of some other foetal structural abnormality, 
and careful follow-up of each case is therefore mandatory. 
5. I suggest a cut-off level of 2.5 mm for the first-trimester NT thickness at 10 
to 13 weeks of gestation. 
6. If the NT thickness is increased, genetic counselling can be essential for the 
parents concerning the prognosis of pregnancy. 
7. The number of pregnants taking part first-trimester screening should be 
increased: 
8. In order to furnish further data on the genesis of trisomies, study of the 
differences between the sex ratios of the autosomal trisomies and molecular 
genetic study of the non-disjunction of the chromosomes of trisomies 13, 18 
and 21 is essential. 
On the basis of our results, 1 recommend the overall introduction of the method 
suggested above during routine first-trimester ultrasound screening. 
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